TY - JOUR
KW - All-cause mortality
KW - Cardiovascular outcomes
KW - Effect modifier
KW - Hospitalization for heart failure
KW - Major adverse cardiovascular events
KW - obesity
KW - Sodium-glucose cotransporter-2 inhibitors
AU - K. Suissa
AU - S. Schneeweiss
AU - A. Douros
AU - H. Yin
AU - E. Patorno
AU - L. Azoulay
AD - Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States. Electronic address: ksuissa@bwh.harvard.edu.
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada; Department of Medicine, McGill University, Montreal, Canada; Institute of Clinical Pharmacology and Toxicology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada.
Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada; Gerald Bronfman Department of Oncology, McGill University, Montreal, Canada.
AN - 36167266
BT - Diabetes Res Clin Pract
DO - 10.1016/j.diabres.2022.110094
DP - NLM
ET - 2022/09/28
LA - eng
N1 - 1872-8227
Suissa, Karine
Schneeweiss, Sebastian
Douros, Antonios
Yin, Hui
Patorno, Elisabetta
Azoulay, Laurent
Journal Article
Ireland
Diabetes Res Clin Pract. 2022 Sep 24;192:110094. doi: 10.1016/j.diabres.2022.110094.
PY - 2022
SN - 0168-8227
EP - 110094
T2 - Diabetes Res Clin Pract
TI - Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes
VL - 192
ER -